About 43,430 Worth Of Akebia Therapeutics Inc. (AKBA) Shares Belongs To Its Director

As of Friday close, Akebia Therapeutics Inc.’s (NASDAQ:AKBA) stock was down -$0.01, moving down -3.66 percent to $0.40. The average number of shares traded per day over the past five days has been 7,258,960 shares. 2 times new highs have been achieved over the past 5 days, with a $0.0040 gain in that time frame. In the last twenty days, the average volume was 4,463,250, while in the previous 50 days, it was 10,794,260.

Since last month, AKBA stock retreated -12.48%. Shares of the company fell to $0.3650 on 08/02/22, the lowest level in the past month. A 52-week high of $3.35 was reached on 03/09/22 after having rallying from a 52-week low of $0.30. Since the beginning of this year, AKBA’s stock price has dropped by -82.52% or -$1.8650, and marked a new high 4 times. However, the stock has declined by -88.21% since its 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Akebia Therapeutics Inc. (AKBA) last reported insider trading activity 64 days ago on Jun 03. GILMAN STEVEN C, the Director of the company, disposed of 4,567 shares for $0.36 on Jun 03. It resulted in a $1,653 divestment by the insider. Burke Steven Keith sold 7,656 shares at an average price of $2.17 on Mar 01. The insider now owns 217,263 shares following the transaction. On Mar 01, CEO and President Butler John P. sold 53,973 shares at $2.17 apiece. The transaction was valued at $117,159.

Valuation Metrics

The stock’s beta is 1.50. Besides these, the trailing price-to-sales (P/S) ratio of 0.34, the price-to-book (PB) ratio of 2.63.

Financial Health

In the three months ended March 30, Akebia Therapeutics Inc.’s quick ratio stood at 1.00, while its current ratio was 1.20, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 47.30% percent. Based on annual data, AKBA earned $60.18 million in gross profit and brought in $213.58 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -152.50%. Return on equity (ROE) for the past 12 months was -266.10%.

According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. AKBA’s revenue rose 15.24% to $59.61 million during the quarter, while net income inched up to $61.7 million. While analysts expected Akebia Therapeutics Inc. to report -$0.29 quarterly earnings, the actual figure was -$0.35 per share, beating the consensus estimate by -20.70%. During the quarter, the company generated -$49.06 million in EBITDA. The liabilities of Akebia Therapeutics Inc. were 509.24 million at the end of its most recent quarter ended March 30, and its total debt was $129.89 million. The value of shareholders’ equity is $183.53 million.

Technical Picture

This quick technical analysis looks at Akebia Therapeutics Inc.’s (AKBA) price momentum. With a historical volatility rate of 53.41%, the RSI 9-day stood at 46.85% on 05 August.

With respect to its five-day moving average, the current Akebia Therapeutics Inc. price is up by +1.02% percent or $0.0040. At present, AKBA shares trade -14.19% below its 20-day simple moving average and -83.47% percent below its 100-day simple moving average. However, the stock is currently trading approximately +24.41% above its SMA50 and -86.14% below its SMA200.

Stochastic coefficient K was 35.83% and Stochastic coefficient D was 25.12%, while ATR was 0.0309. Given the Stochastic reading of 32.09% for the 14-day period, the RSI (14) reading has been calculated as 47.46%.

Analyst Ratings

Akebia Therapeutics Inc. downgraded its rating on Akebia Therapeutics Inc. (NASDAQ: AKBA) to a Neutral in a note to investors on March 31, 2022. The analysts firm previously had an Overweight rating on the stock.Akebia Therapeutics Inc. (AKBA) has been rated Hold by analysts. According to 0 brokerage firms, AKBA is a sell, and 3 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Akebia Therapeutics Inc. stock as buy, with 0 recommending it as overweight.

With a median target price of $1.63, the current consensus forecast for the stock is $1.25 – $2.00. Based on these forecasts, analysts predict Akebia Therapeutics Inc. (AKBA) will achieve an average price target of $1.63.


Please enter your comment!
Please enter your name here

Hot Topics

Related Articles